# Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

> **NCT00831467** · PHASE1,PHASE2 · COMPLETED · sponsor: **CureVac** · enrollment: 48 (actual)

## Conditions studied

- Hormonal Refractory Prostate Cancer

## Interventions

- **BIOLOGICAL:** CV9103

## Key facts

- **NCT ID:** NCT00831467
- **Lead sponsor:** CureVac
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-12
- **Final completion:** 2013-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00831467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00831467, "Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00831467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*